Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Curis Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. JENNIFER JOY SMITH is the busiest examiner for the portfolio, accounting for 1 pending office action. The presence of 2 distinct art units shows that the company's active prosecution is split between different specialized examination groups.
With 2 pending office actions spread among 2 distinct examiners, the company faces a variety of individual examination styles. Because JENNIFER JOY SMITH accounts for 1 pending office action, no single examiner dominates the current workload. This distribution across 2 distinct art units suggests that the underlying technologies may fall under different classification sub-groups within the Biotechnology & Pharmaceuticals sector. Practitioners should prepare for 2 distinct examiners' preferences, as the 2 pending office actions are not concentrated under a single individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMITH, JENNIFER JOY | 1 | — | — |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18226984 | BIOMARKERS FOR FIMEPINOSTAT THERAPY | SMITH, JENNIFER JOY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037697 | METHODS OF TREATING DISEASES AND DISORDERS | HUTTER, GILLIAN A | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18226984 | BIOMARKERS FOR FIMEPINOSTAT THERAPY | SMITH, JENNIFER JOY | 1685 | §101§103§112 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18037697 | METHODS OF TREATING DISEASES AND DISORDERS | HUTTER, GILLIAN A | 1625 | §103DP | Final Rejection | — | Pending | May 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCuris Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jennifer Joy Smith has the most, with 1 of Curis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
